Evidence-informed assessment and treatment of depression in HCV and interferon-treated patients

References

• Arango V, Underwood MD, Boldrini M, Tamir H, Kassir SA, Hsiung S, et al. Serotonin 1A receptors, serotonintransporter binding and serotonin transporter mRNA expression in the brainstem of depressed suicide victims. Neuropsychopharmacology 2001; 25: 892–903
   PubMed Web of Science ®Google Scholar
• Bonaccorso S, Puzella A, Marino V, Pasquini M, Biondi M, Artini M, et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Research 2001; 105: 45–55
   PubMed Web of Science ®Google Scholar
• Brouwer JP, Appelhof BC, Hoogendijk WJG, Huyser J, Endert E, Zuketto C, et al. Thyroid and adrenal axis in major depression: A controlled study in outpatients. European Journal of Endocrinology 2005; 152: 185–191
   PubMed Web of Science ®Google Scholar
• Budziiszewska B, Siwanowicz J, Przegalinski E. The effect of chronic treatment with antidepressant drugs on the corticosteroid receptor levels in the rat hippocampus. Molecular Brain Research 1994; 46: 147–152
   Google Scholar
• Cai W, Khaoustov VI, Xie Q, Pan T, Le W, Yoffe B. Interferon-α-induced modulation of glucocorticoid and serotonin receptors as a mechanism of depression. Journal of Hepatology 2005; 42: 880–887
   PubMed Web of Science ®Google Scholar
• Capuron L, Raison CL, Musselman DL, Lawson DH, Nemeroff CB, Miller AH. Association of exaggerated HPA axis response to initial injection of interferon-alpha with development of depression during interferon-alpha therapy. American Journal of Psychiatry 2003; 160: 1342–1345
   PubMedGoogle Scholar
• Carithers RL, Jr, Sugano D, Bayliss M. Health assessment for chronic HCV infection: Results of quality of life. Digestive Diseases & Science 1996; 41(12 Suppl.)75S–80S
   Google Scholar
• Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. New England Journal of Medicine 1998; 339: 1493–1499
   PubMed Web of Science ®Google Scholar
• Depino A, Ferrari C, Godoy MCP, Tarelli R, Pitossi FJ. Differential effects of interleukin-1β on neurotoxicity, cytokine induction and glial reaction in specific brain regions. Journal of Neuroimmunology 2005; 168(1–2)96–110, Epub 2005
   Google Scholar
• Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon-α-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003; 44: 104–112
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Kunik M, Richardson P, Rabeneck L. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 2002; 123: 476–482
   PubMed Web of Science ®Google Scholar
• Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Annals of Internal Medicine 2002; 136: 288–292
   PubMed Web of Science ®Google Scholar
• Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 209–212
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine 2002; 347: 975–982
   PubMed Web of Science ®Google Scholar
• Gleason OC, Yates WR, Isbell MD, Philipsen MA. An open-label trial of citalopram for major depression in patients with hepatitis C. Journal of Clinical Psychiatry 2002; 63: 194–198
   PubMed Web of Science ®Google Scholar
• Gleason OC, Yates WR, Philipsen MA, Isbell MD, Pollack BG. Plasma levels of citalopram in depressed patients with hepatitis C. Psychosomatics 2004; 45: 29–33
   Google Scholar
• Gleason OC, Yates WR. Five cases of interferon-alpha-induced depression treated with antidepressant therapy. Psychosomatics 1999; 40: 510–512
   PubMed Web of Science ®Google Scholar
• Gohier B, Goeb JL, Rannou-Dubas K, Fouchard I, Cales P, Garre JB. Hepatitis C, alpha interferon, anxiety and depression disorders: A prospective study of 71 patients. World Journal of Biological Psychiatry 2003; 4: 115–118
   PubMed Web of Science ®Google Scholar
• Goldman LS. Successful treatment of interferon-alfa-induced mood disorder with nortriptyline. Psychosomatics 1994; 35: 412–413
   PubMed Web of Science ®Google Scholar
• Grinspoon S, Corcoran C, Stanley T, Baaj A, Basgoz N, Klibanski A. Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. Journal of Clinical Endocrinology and Metabolism 2000; 85: 60–65
   PubMed Web of Science ®Google Scholar
• Gromley GJ, Lowy MT, Reder AT, Hospelhorn VD, Antel JP, Meltzer HY. Glucocorticoid receptors in depression: Relationship to the dexamethasone suppression test. American Journal of Psychiatry 1985; 142: 1278–1284
   Google Scholar
• Hartgers C, Van Den Hoek JAR, Coutinho RA, Van Der Pligt J. Psychopathology, stress and HIV-risk injecting behaviour among drug users. British Journal of Addiction 1992; 87: 857–865
   PubMedGoogle Scholar
• Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Molecular Psychiatry 2002; 7: 942–947
   PubMed Web of Science ®Google Scholar
• Hauser P, Soler R, Reed S, et al. Prophylactic treatment of depression induced by interferon-alpha. Psychosomatics 2000; 41: 439–441
   PubMed Web of Science ®Google Scholar
• Horikawa N, Yamazaki T, Izumi N, Uchihara M. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: A prospective study. General Hospital Psychiatry 2003; 25: 34–38
   PubMed Web of Science ®Google Scholar
• Hosoda S, Takimura H, Shibayama M, Kanamura H, Ikeda K, Kumad H. Psychiatric symptoms related to interferon therapy for chronic hepatitis C: Clinical features and prognosis. Psychiatry & Clinical Neuroscience 2000; 54: 565–572
   PubMed Web of Science ®Google Scholar
• Hutton HE, Treisman GJ, Hunt WR, Fishman M, Kendig N, Swetz A, et al. HIV risk behaviors and their relationship to post-traumatic stress disorder among women prisoners. Psychiatric Services 2001; 52(4)508–513
   PubMed Web of Science ®Google Scholar
• Janssen HLA, Brouwer JT, van der Mast RC, Sclam SW. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. Journal of Hepatology 1994; 21: 241–243
   PubMed Web of Science ®Google Scholar
• Joffe RT. Should thyroid replacement therapy be considered for patients with treatment-refractory depression?. Journal of Psychiatry & Neuroscience 2002; 27: 80
   Google Scholar
• Jozuka H, Jozuka E, Suzuki M, Takeuchi S, Takatsu Y. Psycho-neuro-immunological treatment of hepatocellular carcinoma with major depression—a single case report. Current Medical Research & Opinion 2003; 19: 59–63
   PubMed Web of Science ®Google Scholar
• Kamata M, Higuchi H, Yoshimoto M, et al. Effects of a single intracerebroventricular injection of alpha-interferon on monoamine concentration in the rat brain. European Journal of Neuropsychopharmacology 2000; 10: 129–132
   Google Scholar
• Kraus MR, Schafer A, Bentink T, Scheurlen M, Weissbrich B, Al-Taie O, et al. Sexual dysfunction in males with chronic hepatitis C and antiviral therapy: Interferon-induced functional androgen deficiency or depression?. Journal of Endocrinology 2005; 185: 345–352
   PubMed Web of Science ®Google Scholar
• Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Alimentary Pharmacology & Therapeutics 2002; 16: 1091–1099
   PubMed Web of Science ®Google Scholar
• Laguno M, Blanch J, Murrilas J, Blanco JL, Leon A, Lonca M, et al. Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C. Antiviral Therapy 2004; 9: 905–909
   PubMed Web of Science ®Google Scholar
• Lee DH, Jamal H, Regenstein FG, Perrillo RP. Morbidity of chronic hepatitis C as seen in a tertiary care medical center. Digestive Diseases and Sciences 1997; 42: 186–191
   PubMed Web of Science ®Google Scholar
• Levenson JL, Fallon HJ. Fluoxetine treatment of depression caused by interferon-α. American Journal of Gastroenterology 1993; 88: 760–761
   PubMed Web of Science ®Google Scholar
• Loftis JM, Wall JM, Linardatos E, Benvenga S, Hauser P. A quantitative assessment of depression and thyroid dysfunction secondary to interferon-alpha therapy in patients with hepatitis C. Journal of Endocrinological Investigation 2004; 27: RC16–RC20
   Google Scholar
• Maddock C, Baita A, Orru MG, Sitzia R, Costa A, Muntoni E, et al. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: A prospective case series and a discussion of biological mechanisms. Journal of Psychopharamacology 2004; 18: 41–46
   PubMed Web of Science ®Google Scholar
• Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997; 9: 853–858
   PubMed Web of Science ®Google Scholar
• Malek-Ahmadi P, Ghandour E. Bupropion for the treatment of interferon-induced depression. Annals of Pharmacotherapeutics 2004; 38: 1202–1205
   Google Scholar
• Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958–965
   PubMed Web of Science ®Google Scholar
• Marcellin P, Pouteau M, Benhamou JP. Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction. Journal of Hepatology 1995; 22: 364–369
   Google Scholar
• McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New England Journal of Medicine 1998; 339: 1485–1492
   PubMed Web of Science ®Google Scholar
• Morikawa O, Sakai N, Obrara H, et al. Effects of interferon-alpha, interferon-gamma and camp on the traditional regulation of the serotonin transporter. European Journal of Pharmacology 1998; 349: 317–324
   PubMed Web of Science ®Google Scholar
• Morrill AC, Ickovics JR, Golubchikov VV, Beren SE, Rodin J. Safer sex: Social and psychological predictors of behavioral maintenance and change among heterosexual women. Journal of Consulting & Clinical Psychology 1996; 64: 819–828
   PubMed Web of Science ®Google Scholar
• Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. New England Journal of Medicine 2001; 344: 961–966
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. Management of hepatitis C. Consensus Development Conference Statement. June, 10–122002, 19, 2002
   Google Scholar
• Neumeister A, Wood S, Bonne O, Nugent AC, Luckenbaugh DA, Young T, et al. Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects. Biological Psychiatry 2005; 57: 935–937
   PubMed Web of Science ®Google Scholar
• Pariante CM, Miller AH. Glucocorticoid receptors in major depression: Relevance to pathophysiology and treatment. Psychiatry 2001; 49: 391–404
   Google Scholar
• Regier DA, Farmer ME, Rae DS, Locke BZ, Kieth SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Journal of the American Medical Association 1990; 264: 2511
   PubMed Web of Science ®Google Scholar
• Reindollar RW. Hepatitis C and the correctional population. American Journal of Medicine 1999; 107(6B)100S–103S
   PubMedGoogle Scholar
• Rosenberg SD, Goodman LA, Osher FC, Swartz MS, Essock SM, Butterfield MI, et al. Prevalence of HIV, heaptitis B, and hepatitis C in people with severe mental illness. American Journal of Gastroenterology 2001; 91: 31–37
   Google Scholar
• Schaefer M, Schwaiger M, Garkisch AS, Pich M, Hinzpeter A, Uebelhack R, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. Journal of Hepatology 2005; 42: 793–798
   PubMed Web of Science ®Google Scholar
• Schramm TM, Lawford BR, MacDonald GA, Cooksley WGE. Sertraline treatment fo interferon-alfa-induced depressive disorder. Medical Journal of Australia 2000; 173: 359–361
   PubMed Web of Science ®Google Scholar
• Song C, Lin A, Bonaccorso S, et al. The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. Journal of Affective Disorders 1998; 49: 211–219
   PubMed Web of Science ®Google Scholar
• Van West D, Maes M. Activation of the inflammatory response system: A new look at the etiopathogenesis of major depression. Neuroendocrinology Letters 1999; 20: 11–17
   PubMedGoogle Scholar
• Whalley LJ, Borthwick N, Copolov D, Dick H, Christie JE, Fink G. Glucocorticoid receptors and depression. British Journal of Medicine Clinical Research Edition) 1986; 292: 859–861
   PubMedGoogle Scholar
• Widner B, Ledochowski M, Fuchs D. Interferon-gamma-induced tryptophan degradation: Neuropsychiatric and immunological consequences. Current Drug Metabolism 2000; 1: 193–204
   PubMed Web of Science ®Google Scholar
• Williams I. Epidemiology of hepatitis C in the United States. American Journal of Medicine 1999; 107(6B)2S–9S
   PubMedGoogle Scholar
• Xia Z, DePiere JW, Nassberger L. Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T-cells. Immunopharmacology 1996; 34: 27–37
   PubMed Web of Science ®Google Scholar
• Yoshida K, Alagbe O, Wang X, Woolwine B, Thornbury M, Raison CL, et al. Promoter polymorphisms of the interferon-α receptor gene and development of interferon-induced depressive symptoms in patients with chronic hepatitis C: Preliminary findings. Neuropsychobiology 2005; 52: 55–61
   Google Scholar